# Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors

Source: https://onco.cc/trials/nct05367778/  
OnCo record `nct05367778` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of HS-10370 in advanced solid tumours, run by Jiangsu Hansoh Pharmaceutical Co., Ltd., now recruiting.

## Summary

Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05367778 by Jiangsu Hansoh Pharmaceutical Co., Ltd., with 176 participants planned, started 2022-06-03 and due to reach its primary completion in 2025-04-30. Interventions recorded: HS-10370.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05367778
- Phase: 1/2
- Setting: A Phase 1/2, Open-label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-10370 Monotherapy in Patients with Advanced Solid Tumors
- Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Enrolled: 176

## Sources

- ClinicalTrials.gov NCT05367778: https://clinicaltrials.gov/study/NCT05367778

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct05367778.json